Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Risk Assessment and Treat Compliance in Hypertension Education Trial (RATCHET)

This study has been completed.
Sponsor:
Collaborators:
University of Western Ontario, Canada
The Physicians' Services Incorporated Foundation
Information provided by:
Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT00694239
First received: June 6, 2008
Last updated: June 29, 2011
Last verified: June 2011

June 6, 2008
June 29, 2011
May 2007
March 2011   (final data collection date for primary outcome measure)
Medication Compliance [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00694239 on ClinicalTrials.gov Archive Site
  • Patient perception of cardiovascular risk [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Pilot Feasibility Study [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Blood Pressure [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Cholesterol Level [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Framingham Risk Score (stroke and coronary artery disease) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Risk Assessment and Treat Compliance in Hypertension Education Trial
Evaluation of the Effect of Cardiovascular Risk Assessment in Treatment Compliance in Hypertension

The RATCHET study assesses if patient knowledge of estimated cardiovascular risk at current and recommended target blood pressure levels improves compliance in the management of hypertension.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Hypertension
  • Dyslipidemia
Behavioral: Knowledge of Cardiovascular Risk Assessment
Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
  • No Intervention: B
    Standard Care
  • Experimental: A
    Risk Assessment plus standard care
    Intervention: Behavioral: Knowledge of Cardiovascular Risk Assessment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
March 2011
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Essential hypertension (new diagnosis or established diagnosis) meeting criteria for pharmacologic therapy as defined by current guidelines

Exclusion Criteria:

  • Lack of written informed consent
  • Previous myocardial infarction
  • Previous stroke
  • Congestive heart failure
  • Stage 3 or greater chronic kidney disease
  • Pregnancy
  • Usage of medication bubble/blister package
Both
30 Years to 84 Years
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00694239
R-07-053, 13014E
Yes
George Dresser, University of Western Ontario
Lawson Health Research Institute
  • University of Western Ontario, Canada
  • The Physicians' Services Incorporated Foundation
Principal Investigator: Bryan J Har, MD University of Western Ontario, Canada
Principal Investigator: George K Dresser, PhD, MD University of Western Ontario, Canada
Lawson Health Research Institute
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP